The expression levels of several NER proteins [e.g., xeroderma pigmentosum complementation group A/C/G (XPA/C/G), excision repair cross-complementation group 1–xeroderma pigmentosum complementation group F (ERCC1-XPF)] and somatic mutations in XPD significantly affect cellular sensitivity to cisplatin [86,87]. The gene discussed is ERCC1; the disease is xeroderma pigmentosum.